These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33916702)

  • 21. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
    Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
    Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
    Gao M
    Curr Opin Virol; 2013 Oct; 3(5):514-20. PubMed ID: 23896281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China.
    Nie B; Guo Y; Zhang K; Liu J; Yun S
    Arch Virol; 2020 Sep; 165(9):2013-2020. PubMed ID: 32601956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells.
    Ikeda M; Yi M; Li K; Lemon SM
    J Virol; 2002 Mar; 76(6):2997-3006. PubMed ID: 11861865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
    El-Shamy A; Shoji I; Saito T; Watanabe H; Ide YH; Deng L; Kawata S; Hotta H
    Microbiol Immunol; 2011 Jun; 55(6):418-26. PubMed ID: 21371092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus.
    Soria ME; Gregori J; Chen Q; García-Cehic D; Llorens M; de Ávila AI; Beach NM; Domingo E; Rodríguez-Frías F; Buti M; Esteban R; Esteban JI; Quer J; Perales C
    BMC Infect Dis; 2018 Sep; 18(1):446. PubMed ID: 30176817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing.
    Abe H; Hayes CN; Hiraga N; Imamura M; Tsuge M; Miki D; Takahashi S; Ochi H; Chayama K
    Am J Gastroenterol; 2013 Sep; 108(9):1464-72. PubMed ID: 23896953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity of a ribavirin resistant mutant of hepatitis C virus to other antiviral drugs.
    Mihalik KB; Feigelstock DA
    PLoS One; 2013; 8(9):e74027. PubMed ID: 24040153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.
    Sugihara K; Orito E; Tanaka Y; Kato T; Lau JY; Ohno T; Hayashi K; Ogino M; Hirashima N; Sakakibara K; Mizuno Y; Kato H; Suzuki S; Ueda R; Mizokami M
    Intervirology; 2006; 49(6):319-26. PubMed ID: 16926544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein.
    Vogt DA; Camus G; Herker E; Webster BR; Tsou CL; Greene WC; Yen TS; Ott M
    PLoS Pathog; 2013; 9(4):e1003302. PubMed ID: 23593007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
    McPhee F; Hernandez D; Zhou N; Ueland J; Yu F; Vellucci V; Huang X; Wang X; Ishikawa H; Karino Y; Kumada H
    Antivir Ther; 2018; 23(1):53-66. PubMed ID: 28594332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
    Ullah S; Rehman HU; Idrees M
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture.
    Oraby AK; Gardner CL; Needle RF; Kofahi HM; Everard KR; Taylor NGA; Rutihinda SG; Barry JP; Hirasawa K; Georghiou PE; Russell RS
    Microbiol Spectr; 2021 Sep; 9(1):e0043921. PubMed ID: 34319169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome.
    Mihm U; Hofmann WP; Welsch C; Polta A; Lengauer T; Zeuzem S; Sarrazin C; Herrmann E
    J Viral Hepat; 2010 Mar; 17(3):217-21. PubMed ID: 19758279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.
    Imhof I; Simmonds P
    J Virol; 2010 May; 84(9):4597-610. PubMed ID: 20164226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell culture-adaptive mutations in hepatitis C virus promote viral production by enhancing viral replication and release.
    Wang Q; Li Y; Liu SA; Xie W; Cheng J
    World J Gastroenterol; 2018 Mar; 24(12):1299-1311. PubMed ID: 29599605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
    Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.